Antiviral Drugs - Market Insights, Competitive Landscape, and Market Forecast - 2030

Antiviral Drugs Market By Drug Class (Dna Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Neuraminidase Inhibitors, Protease Inhibitors, And Others), By Indication (Hiv Infection, Herpes, Hepatitis, Influenza, And Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, And E-Commerce), and by geography is expected to advance at a respectable CAGR forecast till 2030 owing to the increasing prevalence of various infectious diseases such as influenza, hiv, hepatitis, and others and the increasing initiatives to curb the viral diseases by public and private companies across the globe

The global antiviral drugs market will grow at a CAGR of 3.65% during the forecast period from 2024 to 2030 to reach USD 51,466.21 million by 2030. The antiviral drugs market is observing substantial market growth owing to the increasing prevalence of HIV, hepatitis, Ebola, and other viral diseases across the globe. Further, the growing initiatives for the awareness of viral diseases and the increasing geriatric population base prone to viral diseases will also aid in increasing the demand for antiviral drugs. Additionally, the rising advancements in antiviral drugs such as proteolysis targeting chimera mechanism, targeted covalent inhibitor mechanism, and others to improve the efficacy of the drug will spur the market of antiviral drugs. Similarly, the increasing research & developmental activities along with the surging drug approvals and launches, and the presence of key players in the market, are some of the key factors that will create a requisite for antiviral drugs in the market. Therefore, the market for antiviral drugs is estimated to grow at a substantial CAGR during the forecast period from 2024 to 2030.

Antiviral Drugs Market Dynamics:

As per the World Health Organization (WHO) 2022, nearly 38.4 million people were living with HIV infection in 2022, globally. The source also stated that nearly 36.7 million were adults (aged 15 and above) and approximately 1.7 million people were children, aged less than 15 years.

The source UNAIDS 2022 report added that nearly 1.5 million people became newly infected with HIV infection, in 2022, globally. The aforesaid source also mentioned that in 2022, 28.7 million people were accessing antiretroviral therapy, globally.

Furthermore, the Joint United Nations Programme on HIV and AIDS also estimated that as of June 2020, 26 million people were accessing antiretroviral therapy, whereas, in 2019, about 25.4 million people were getting antiretroviral therapy. The data suggest that access to anti-viral therapeutic drugs is continuously increasing across the world, which is acting as one of the major factors propelling the market growth. Thus, the increasing prevalence of HIV infection and the increasing awareness regarding the infection will ultimately increase the demand for antiviral drugs used in the treatment of HIV infection.

Additionally, the growing research and developmental activities, expanding product launches and approvals around the world, presence of a robust number of drugs in the pipeline, and strategic activities by the key players to increase the manufacturing and research for the anti-viral drugs will in turn bolster the market of antiviral drugs. For instance, in April 2022, Atriva Therapeutics GmbH, a biopharmaceutical company specifically pioneering the development of host-targeting antiviral therapies received EUR 11.4 million in federal funding. The company has planned to use the funds to advance its drug ATR-002, which is currently in a Phase II clinical study called RESPIRE.

Also, in January 2022, Gilead Sciences, Inc., announced that the U.S. Food and Drug Administration (FDA) has granted expedited approval of a supplemental new drug application (sNDA) for Veklury® (remdesivir) for the treatment of non-hospitalized adult and adolescent patients who are at high risk of progression to severe COVID-19, including hospitalization or death. This approval expands the role of Veklury, which is the antiviral standard of care for the treatment of patients hospitalized with COVID-19.

Furthermore, advances in molecular biology are promoting drug development in tandem with the growing use of nucleoside and nucleotide analogs as first-line antivirals. According to the market's current development pipeline, many small molecule-based anti-viral drugs are expected to receive product approvals in the future, propelling market growth to unprecedented heights during the forecast period.

Therefore, the factors stated above collectively will drive the overall antiviral drugs market during the forecast period from 2024-2030.

However, the emergence of antiviral drug resistance, side effects associated with antiviral drugs, the high cost of the therapy, and the stringent regulatory approval process may prove to be challenging factors for antiviral drug market growth.

The antiviral drugs market was positively impacted during the period of COVID- 19 pandemic as they were used to prevent the spread of the SARS-CoV-2 virus, along with other infectious agents. Although during the initial stage of the lockdown, the market suffered a downfall owing to the strict lockdown restrictions and disruption in manufacturing, and supply chains. However, as the demand for antiviral drugs upsurges the key players in the market accelerated their manufacturing. Many key players indulged in strategic decisions, investments, and research & developmental activities concerning antiviral drugs, leading to an increased demand for antiviral drugs. Moreover, in October 2020, the U.S. Food and Drug Administration approved the antiviral drug Veklury (remdesivir) for use in adult and pediatric patients 12 years of age and older for the treatment of COVID-19 requiring hospitalization. Henceforth, the wide use of antiviral drugs for the prevention of the spread of COVID-19 among the population significantly contributed to the positive growth of the Antiviral drugs market over the forecast period (2022 - 2028).

Antiviral Drugs Market Segment Analysis:

Antiviral Drugs Market by Drug Class (DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Neuraminidase Inhibitors, Protease Inhibitors, and Others), Indication (HIV Infection, Herpes, Hepatitis, Influenza, and Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and E-Commerce), and Geography (North America, Europe, Asia-Pacific, and Rest of the World).

In the indication segment of the antiviral drugs market, influenza is expected to have a significant revenue share in the year 2023. This was primarily owing to the rising demand and availability of antivirals drugs in the market owing to the increasing prevalence of various viral diseases, expanding launches and strategic investments and other activities relating to antiviral drugs by key players in the market, and wide application and advantages offered by the segment. Lastly, the increasing burden of covid-19 infection across the globe aids in growing the demand for influenza-treating antiviral drugs.

For instance, as per the Centers for Disease Control and Prevention (CDC), from September 28, 2020, to May 22, 2022, in the United States, 1,675 (0.2%) of 818,939 respiratory specimens tested by US clinical laboratories were found positive for an influenza virus.

Also, as per the WHO Virological Surveillance Summary 2022, from week 1, 2022 to week 44, 2022, nearly 54,051 of 418,329 were found positive for an influenza virus in China. The enlarged diagnosis of influenza across various regions across the globe is expected to affect the market optimistically, as more patients will reach out for antiviral therapies after being diagnosed.

Furthermore, surging research and developmental activities, drug launches and approvals, the presence of a robust number of influenza-treating antiviral drugs in the pipeline, and other factors will create a productive opportunity for market growth during the upcoming years. For instance, in November 2022, Seqirus, a global leader in influenza, announced that the U.S. Food and Drug Administration (FDA) has granted supplemental approval of a multi-dose vial (MDV) formulation of AUDENZ(TM) (Influenza A (H5N1) Monovalent Vaccine, Adjuvanted), the first-ever adjuvant, cell-based influenza vaccine designed to help protect individuals six months of age and older against influenza A (H5N1) in the event of a pandemic.

Also, in October 2019, the US Food and Drug Administration (FDA) approved a supplemental new drug application (sNDA) of Xofluza (baloxavir marboxil) to treat acute, uncomplicated influenza (flu). The drug is indicated for individuals aged 12 years and above experiencing symptoms for no more than 48 hours and at high risk of flu-related complications.

Therefore, owing to the above-mentioned factors, the demand for influenza drugs upsurges, thereby the category is expected to witness considerable growth eventually contributing to the overall growth of the global antiviral drugs market during the forecast period.

North America is expected to dominate the overall Antiviral Drugs Market:

Among all the regions, North America is expected to dominate the global antiviral drugs in the year 2023 and is expected to do the same during the forecast period from 2024-2030.

This can be ascribed to the increasing demand for antiviral drugs in the region owing to the increasing prevalence of many viral and infectious diseases, the increasing geriatric patient pool suffering from viral diseases, the growing initiatives for the awareness of viral diseases, the launch of new drugs, the presence of key market players in the region, and others are among the key factors that contribute to the growth of the antiviral drugs market in North America.

For instance, according to the latest estimates from the Centers for Disease Control and Prevention (CDC), approximately 34,800 new HIV infections occurred in the United States in 2019. Also, at year-end 2019, an estimated 1.2 million people in the United States aged 13 and older had HIV in the United States. Thus, the increasing prevalence of HIV infection in the United States will increase the demand for many antiviral drugs.

Furthermore, according to the latest study conducted by the U.S. Department of Health & Human Services, approximately 2.4 million people were estimated to be living with hepatitis C in the United States and nearly 850,000 people in the US were estimated to be living with hepatitis B, in 2022.

Additionally, the spread of the pandemic in the region also impacted the market of antiviral drugs.

Moreover, the antiviral drug launches, regulatory approvals, and other activities such as acquisitions, and agreements, in the region will lead to its increased demand in the market. For instance, in August 2020, ViiV Healthcare, the global specialist HIV Company headquartered in the United States, received the US Food and Drug Administration (FDA) approval for its Dovato as a complete regimen for the treatment of HIV-1 infection to replace the current antiretroviral (ARV) regimen in adults who are virologically suppressed.

Additionally, to upsurge the market growth of antiviral drugs, the federal government is providing support funds to pharmaceutical companies to help them to strengthen their clinical development pipelines. For instance, in July 2020, Novavax and Regeneron received USD 2 billion in funding from the US federal government to manufacture drugs and vaccines against COVID-19.

Moreover, the presence of sophisticated healthcare infrastructure and high awareness among end-users such as clinicians and healthcare professionals are estimated to be the key growth drivers. Also, the presence of favorable reimbursement policies is anticipated to further fuel North America's antiviral drugs market during the forecast period (2022 - 2028).

Therefore, the interplay of the aforementioned factors above would provide a conducive growth environment for the North America region in the antiviral drugs market.

Antiviral Drugs Market Key Players:

Some of the key market players operating in the antiviral drugs market include AbbVie Inc., Bristol-Myers Squibb Company, Gilead Sciences, Inc., F. Hoffmann-La Roche Ltd, Pfizer Inc., Cipla Inc., Lupin., ENTOD INTERNATIONAL, AstraZeneca, Dr. Reddy's Laboratories Ltd., GSK plc., Johnson & Johnson, Merck & Co., Inc., Novartis AG, Sanofi, ViiV Healthcare, Aurobindo Pharma., Sun Pharmaceutical Industries Ltd., Viatris Inc., Boehringer Ingelheim, and others.

Recent Developmental Activities in the Antiviral Drugs Market:

In January 2022, Lupin launched the anti-viral drug Molnupiravir in India under the brand name Molnulup for the treatment of adults suffering from COVID-19 in the country.

In January 2022, ENTOD Pharmaceuticals launched MOLENTOD in India. The product will be available at retail chemists, pharmacy chains, hospitals, and online stores at an affordable price.

In December 2022, the U.S. Food and Drug Administration (FDA) granted an emergency use authorization (EUA) to molnupiravir for use in certain populations where other treatments are not feasible.

In October 2020, Roche announced a partnership with Atea Pharmaceuticals to develop, manufacture, and commercialize Atea's AT-527, an investigational oral antiviral drug for the COVID-19 treatment. This partnership has enhanced the firm's development potential, thus strengthening its market position.

In May 2020, Cipla and Gilead Sciences entered a partnership alliance to develop and commercialize the investigational medicine being used to treat COVID-19-affected patients.

Key Takeaways from the Antiviral Drugs Market Report Study

• Market size analysis for current antiviral drugs market size (2023), and market forecast for 5 years (2024-2030)
• The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the antiviral drugs market.
• Top key products/services/ developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
• Key companies dominating the global antiviral drugs market.
• Various opportunities available for the other competitor in the antiviral drugs market space.
• What are the top-performing segments in 2023? How these segments will perform in 2030.
• Which are the top-performing regions and countries in the current antiviral drugs market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for antiviral drugs market growth in the coming future?

Target Audience who can be benefited from this Antiviral Drugs Market Report Study

• Antiviral drugs products providers
• Research organizations and consulting companies
• Antiviral drugs -related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and Traders dealing in antiviral drugs
• Various end users who want to know more about the antiviral drugs market and the latest developments in the antiviral drugs market.

Frequently Asked Questions for the Antiviral Drugs Market:

1. What are antiviral drugs?

Antiviral drugs are a class of medication used for treating viral infections. Most antivirals target specific viruses, while a broad-spectrum antiviral is effective against a wide range of viruses.

2. What is the global market for antiviral drugs?

The global antiviral drugs market will grow at a CAGR of 3.65% during the forecast period from 2024 to 2030 to reach USD 51,466.21 million by 2030.

3. What are the drivers for the global antiviral drugs market?

The antiviral drugs market is witnessing positive market growth owing to the factors such as the growing prevalence of various infectious diseases such as HIV, herpes, influenza, and others, growing initiatives for the awareness of infectious diseases, increasing geriatric population base prone to various infectious diseases such as influenza, hepatitis, rising strategic steps by the key players for the development and manufacturing of antiviral drugs, increasing new drug launches and approvals, presence of key players in the market, and others will create an exigency for the antiviral drugs market.

4. Who are the key players operating in the global antiviral drugs market?

Some of the key market players operating in the Antiviral drugs market include AbbVie Inc., Bristol-Myers Squibb Company, Gilead Sciences, Inc., F. Hoffmann-La Roche Ltd, Pfizer Inc., Cipla Inc., Lupin., ENTOD INTERNATIONAL, AstraZeneca, Dr. Reddy's Laboratories Ltd., GSK plc., Johnson & Johnson, Merck & Co., Inc., Novartis AG, Sanofi, ViiV Healthcare, Aurobindo Pharma., Sun Pharmaceutical Industries Ltd., Viatris Inc., Boehringer Ingelheim, and others.

5. Which region has the highest share of the antiviral drugs market?

Among all the regions, North America is estimated to hold a significant revenue share in the global antiviral drugs market. This can be ascribed to the increasing demand for antiviral drugs among the patients in the region owing to the increasing prevalence of HIV, hepatitis, covid-19, and other viral diseases. Further, the growing initiatives for the awareness of viral diseases, the increasing geriatric population base prone to viral diseases, and the presence of key domicile players in the region are the reasons which act as a supportive factor for the North American antiviral drugs market growth.